VOL.46 NO.9 THE JOURNAL OF ANTIBIOTICS 1459 be explained partly by the hydrogen bond (Scheme 1) observed between the amidic NHand the carbonyl of the quinolone ring (1: NMR 3 10.4ppm in DMSO-d6 compared to 8.3ppm for normal amidic compounds) which result in a planar C-3' substituent1}.
In order to understand the role played by the planar conformation of the C-3' substituent and to further improve the type I /Mactamase stability, we decided to replace this labile hydrogen bond by a covalent one as in 3 (Scheme 1). The synthesis and biological properties of these new compoundsare described in this paper.
Chemistry
The strategy used to prepare C-3' ortho dihydroxyphthalimido cephalosporins10) 3~7 involves
Af-carboethoxyphthalimides 23~25, 37, 38 as intermediates. Such reagents are known to react smoothly with amines to give the corresponding iV-phthalimido protected compound in good yield11*. Thus we synthesized the functionalised catechol phthalimides 23~25, 37, 38 and reacted them with the C-3' aminomethyl cephalosporin 41 1}. 3 ,4-Dimethoxytoluene was formylated using dichloromethylmethyl ether in the presence of tin chloride to give the aldehyde 10 (Scheme 2). The brominated isomer ll was obtained from vanillin after monobromination and similar formylation. 10, ll were then oxidized with KMnO4 to give the diacids 12, 13 which were transformed into the corresponding phthalimides 14, 15 via the intermediate anhydrides. After deprotection of the catechol moiety using BBr3, 17 was chlorinated using Af-chlorosuccinimide and paratoluenesulfonic acid. In order to avoid side reactions during the iV-carboethoxylation step, the catechol moiety was reprotected with an acid labile group; the most convenient proved to be the diphenylmethyl moiety. Protected phthalimides 20~22 were then reacted with NaHfollowed by ethyl chloroformate to
give reagents 23~25.
Condensation of 23~25 with 41 in DMSO occurs smoothly at room temperature and the protected cephalosporins 26~28 were isolated in very good yield. Final deprotection of the catechol moiety was achieved using trifluoroacetic acid in the presence of traces of water to give the free ortho dihydroxyphthalimido cephalosporins 3~5 (Scheme 2).
A similar strategy was used to generate the isomeric series, cephalosporins 6 and 7 (Scheme 3). In addition, compound8 (Table 1 ) used here as a comparator was obtained following a similar sequence starting from commercially available N-carboethoxyphthalimide.
Biological Results and Discussion MIC values (/xg/ml) of the C-3' ortho dihydroxyphthalimido cephalosporins 3~7 against a selection of Gram-positive and Gram-negative bacteria are shown in Table 1 . Compounds3^7 have been compared with cephalosporin 1 and 2 (Scheme 1) and with classical standards.
A first look at Table 1 shows that activities of phthalimides 3~7 are superior to simple monocyclic catechols such as 9 (Table  1) having a phenolic pATa«9, against E. cloacae, P. stuartii, C. freudii, S. marcescens and P. morganii. Against P. aeruginosa 3~7 are equivalent to 9. The level of activity against Gram-negative organisms obtained with the parent deshydroxyphthalimido cephalosporin 8, compared with phthalimides 3~5 underlines clearly the importance of the orj/w-dihydroxy function.
Comparison of biological activities against P. aeruginosa 799/61 and Escherichia coli DC2, the permeability mutants lacking the outer membrane of 799WTand DCO,respectively, shows that 3~5 Scheme 2. Synthesis ofcephalosporines 3, 4, and 5.
Scheme 3. Synthesis of cephalosporines 6 and 7.
CH3COOH, g) Ph2CCl2, h) 1) NaH, THF, 2) ClCO2Et, i) 41, Et3N, DMSO, j) TFA, H2O.
(MIC's: 0.001 -0.008 /zg/ml) and the parent 8 (MIC: 0.008 /ig/ml) have similar intrinsic activity. However comparison of activities against P. aeruginosa 799WTand E. coli DC0and their permeability mutants 799/61 and DC2, respectively shows that molecules 3-5 bearing a catechol residue at C-3' penetrate well into bacteria (ratio 799WT/799/61: 3-5= 1 to 2; Ceftazidime =30) while 8 is much less efficient (ratio 799WT/799/61 = 1,000). The result of passive diffusion is well represented by the activity of 8 against P. aeruginosa 799WT (MIC = 8 jug/ml). This clearly indicates that the catechol moiety facilitates the penetration through the outer membrane of bacteria. The mechanism of penetration has been shown to be ton B dependent8*, the known functionality of the ton B gene product concerning the transport of iron-chelated siderophores in E. coli.
Against Gram-positive organisms 3-5 are less active than cefpirome and cefepime. Against Streptococcus pneumoniae and Streptococcus pyogenes 4 and 5 are just equivalent to ceftazidime, 4 being the best compound.
Against inducible
and derepressed type I /Mactamase-producers (see Table 1 , footnotes b, e) P. aeruginosa, Enterobacter cloacae, Providencia stuartii, Citrobacter freundii, Serratia marcescens, Proteus morganii and Klebsiella oxytoca, C-3' ortho dihydroxyphthalimido cephalosporins 3-7 are superior to Measured by bioassay.
ceftazidime. 3~7 also proved to be 2 to 100 times more active against constitutive derepressed and inducible type I /Mactamases-producing strains than cefepime and cefpirome ( Table 1) .
Comparison of mic's against /Mactamase-derepressed producers ( 9: ratio= 1,067, ceftazidime: ratio= 1,024). Similar comparisons indicates ( Table 1 ) that C-3' ortho dihydroxyphthalimido cephalosporins 3 -7 are marginally more stable to /Mactamases than cefepime and cefpirome, the accepted type I "stable cephalosporins", against E. cloacae (comparison P99+/P99") and C.freundii (I + 38201 0/DR38203 1) but are very similar against E. cloacae (comparison I +401029/DR40 1 108), P. stuartii, S. marcescens and P. morganii (see Table 1 ).
Overall the activity and stability against constitutive and inducible derepressed type I /Mactamaseproducing strains has been improved. These results showed clearly that the stability observed in compounds possessing an H-bonding between the NHof the C-3' amidic linkage and the carbonyl group of the quinolone moiety (Scheme 1) (comparison of 1 and 2) has been reinforced in phthalimido catechol cephalosporin such as 3. Furthermore the bulk of C-3' phthalimido substituents as well as the acidity of the OHof the ortho-dihy&roxy moiety reinforce the observation that hindrance at C-3' and acidity of the catechol1'9* improves the /Mactamase stability.
The pharmacokinetics of 5 and 7 measured in the marmoset (Table 2) were equivalent to those of ceftriaxone, an injectable cephalosporin suitable for once-daily dosing. 4 is clearly superior as measured by either half-life or the elevation of serum level which results in higher AUC's. As previously observed9) these pharmacokinetic parameters seem related to the pKa. of the catechol moiety: molecules highly ionised at physiological pH have the longest pharmacokinetics ( Table 2 comparison (Table 2) indicates that additionnal factors can modulate the pharmacokinetics of such compounds. Amongstthem we could probably suspect the serum protein binding and the ability of catechol-cephalosporins to be metabolized by the enzyme catechol-O-methyltransferase (COMT) 1 2). Urinary recoveries (measured in marmosets, single iv dose of 3mg/kg) of these compounds are equivalent to ceftriaxone; values of «25% suggest a significant degree of biliary excretion. All three compounds are highly found to Humanserum protein (measured at 50 mg/liter), ranking from 94%for 3 (equivalent to ceftriaxone) to 99.6% for 4 and 98% for 5. IR spectra were recorded as KBr pellets on a Perkin-Elmer 781 spectrophotometer. XHNMRwere recorded on a JEOLFX90Qor a Brucker 300ACspectrometer. FABmass spectra were obtained on a VG7250 SA mass spectrometer. Analytical HPLCchromatography was carried out on Shimadzu LC6A apparatus using nucleosil C18 5 /mi columns, eluent MeOH-H2Owith 1 : 100 AcOH.Preparative medium pressure chromatography was carried out using Mitsubishi HP20SSresin, eluent MeOH-H2Owith 1 : 100 AcOH. C-3'-Aminomethyl cephalosporin 41 was described in the literature1'13). 2-Carboxy-4,5-dimethoxybenzoic Acid (12) To aldehyde 10 (5g, 44.4mmol) and potassium carbonate (5g) in water (21 ml) at 80°C was added, in one portion, a solution of potassium permanganate (19 g) in water (170ml). The solution was heated at 90~95°C for 1 hour, cooled, neutralized with 5 n HC1 (50ml) and filtered through diatomaceous earth. The aqueous phase was concentrated and extracted into ethyl acetate; the organic phase was dried and evaporated to give 2-carboxy-4,5-dimethoxybenzoic acid (2.85 g); *H NMR(CDC13 -DMSO-d6) S 3.95 (s, 6H), 7.5 (s, 2H), ll. IR vmaxcm"y3750-3200, 1700.
,4-Dimethoxyphthalimide (14)
The di-acid 12 (1.5g, 6.6mmol) and acetic anhydride (6g) were heated at reflux for 1 hour. The mixture was cooled and evaporated to provide dimethoxyphthalic anhydride (1.28 g); *H NMR(DMSO-d6)
£3.99 (s, 6H), 7.6 (s, 2H) .
To the crude anhydride (2.0 g, 9.6mmol) was added 28% ammonia solution (2.3 g ) and the solution was taken to boiling-point, eliminating water in order to obtain a thick paste.
This was cooled to give a brown solid which was finely ground. This solid was heated by a flame SEPT. 1993 (without fusion) to give dimethoxyphthalimide16) (1.7 g). The reaction was monitored by HPLC. 14 was recristallized using EtOH-petroleum ether. *H NMR(DMSO-</6) S 3.9 (s, 6H), 7. 3 ,4-Dihydroxyphthalimide (17) To the dimethoxyphthalimide 14 (3.1 g,.14.9mmol) were added BBr3 (12ml) and dichloromethane (30 ml). The suspension was stirred at ambient temperature until HPLCshowed that starting material had disappeared. Excess solvent was evaporated and the resultant solid cooled to 0°C and treated with ice and then with water (80ml). The mixture was stirred for 45 minutes at ambient temperature, water (40ml) removed by evaporation and the residue purified by column chromatography to provide dihydroxyphthalimide 17 (2.13g); XH NMR (DMSO-</6) S 7.1 (s, 2H), 10.25 (brs, 2H), ll.25 (brs, 1H). Dihydroxyphthalimides 18, 33 were prepared in a similar way: 18: yield 95%; XH NMR(DMSO-d6) £7.1 (s, 1H); IR v^cm"1 3600-2900, 1760, 1720-1700. Anal Calcd for C8H4NO4Br: C 37. (4 g) was heated at 160°C for 3 hours. The resultant solution was cooled and washed with petroleum ether (3 x 10ml). The petrol phase was separated to give a brown oil which was collected and triturated under diethyl ether (5 ml) to give as a chestnet brown solid, diphenylmethylenedioxyphthalimide 20 (300 mg); *H 7V-Carboethoxy-3 ,4-diphenylmethylenedioxyphthalimide (23) To a suspension of sodium hydride (4mg, 50%) (washed with tetrahydrofuran) was added, dropwise, a solution of phthalimide 20 (500mg, 1.45mmol), in DMF(1.5ml). The mixture was stirred for 1 hour at ambient temperature, cooled to 0°C and ethyl chloroformate (180 fA) was added dropwise. The resultant solution was stirred at 0°C for 5 minutes, stirred at ambient temperature for 3 hours, cooled to 0°C and water (5 ml) added with stirring. The solution was extracted with diethyl ether (150ml). The ether phase was washed with water (3 x20ml), saturated NaCl (20ml), dried, filtered and evaporated to give AT-carboethoxy diphenylmethylenedioxyphthalimide (600 mg); JH NMR(CDC13) S 1.40 (t, 3H), 4.45 (q, 2H), 7.25-7.75 (m, 12H) .
iV-Carboethoxyphthalimides 24, 25, 37 and 38 were prepared in a similar way. Compounds 23, 24, 38 decomposes partially when purified over silica or HP20SS resines and have thus been used crude in the next step.
24: yield 95%; XH NMR (DMSO-d6-CF3COOD) S 1.3 (t, 3H), 4.3 (q, 2H), 7.25-7.75 (m, llH 
aminomethylceph-3-em-4-carboxylic acid 41 (143 mg) in DMSO(2 ml) was added triethylamine (62.4 mg) followed by the phthalimide 23 (85.6mg, 0.21 mmol) in DMSO(1 ml).
The solution was stirred at ambient temperature for 90 minutes, concentrated HC1(10 drops) added and after storage at 3°C for 12 hours the solution was evaporated and purified by column chromatography using HP20SS resin to give 26 (70mg); lH NMR(DMSO-d6-CF3GOOD) 8 1.5 (2s, 6H), 3.3 (d, 1H) 
26) (70 mg) was added tri- SEPT. 1993 fluoroacetic acid (4ml) followed by water (2 drops).
The solution was stirred for 4 hours at ambient temperature. The solvent was removedby evaporation and the solid residue was diluted with dimethylformamide (3 ml) and subjected to column chromatography using HP20SS resin to afford the title compound (30mg); XH NMR(DMSO-d6 -CD3COOD-CF3COOD) 2,3-Dihydroxy-4-bromophthalimide (34) A solution of phthalimide 33 (0.26g, 1.4mmol) and bromine (0.23 g, 1.4mmol) in acetic acid (13 ml) was stirred 3 hours at 50°C. After 3 hours a further portion of bromine (0.23 g) in acetic acid (3ml) was added and heating continued for 1 hour at 50°C and 3 hours at 80°C. After cooling and filtration the precipitate was washed with acetic acid and dried to give 34 (350mg); yield: 100%; *H NMR(DMSO-d6) SIA (s, 1H); IRv^cm"1 1750, 1700. 
Conclusion
Introduction of an ortho dihydroxyphthalimido residue at C-3' of the cephalosporin nucleus has led to compounds possessing exceptional in vitro antibacterial activity against Gram-negative becteria, in particular P. aeruginosa. Furthermore these compoundshave shownexceptional /Mactamasestability, this being related to the planarity of the substituent and to the p£a of the catechol moiety. In the marmosets, several of these compounds also possess outstanding pharmacokinetics (equivalent or superior to ceftriaxone) which seemed highly dependent on the pK&of the hydroxy groups.
